

BAXTER INTERNATIONAL INC.
Adjusted Key Product Line Sales
Periods Ending December 31, 2011 and 2010
(unaudited)
(\$ in millions)

	GAAP Q4 2011 ¹	GAAP Q4 2010 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates	GAAP YTD 2011 ¹	Adjusted YTD 2010	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$578	\$534	8%	7%	\$2,212	\$2,095	6%	3%
Plasma Proteins	397	416	(4%)	(2%)	1,440	1,368	5%	5%
Antibody Therapy	406	386	5%	6%	1,541	1,354	14%	13%
Regenerative Medicine	150	145	3%	3%	580	527	10%	8%
Other ²	44	52	(16%)	(25%)	280	296	(6%)	(15%)
Total BioScience	\$1,575	\$1,533	3%	3%	\$6,053	\$5,640	7%	5%
Medical Products ³								
Renal	\$664	\$626	6%	5%	\$2,530	\$2,389	6%	2%
Global Injectables	487	499	(2%)	(3%)	2,004	1,891	6%	3%
IV Therapies	469	452	4%	4%	1,802	1,678	7%	5%
Infusion Systems - Adjusted ⁴	235	230	2%	2%	901	868	4%	2%
Anesthesia	147	141	4%	4%	537	525	2%	1%
Other	11	8	33%	2%	30	19	56%	8%
Total Medical Products - Adjusted ⁴	\$2,013	\$1,956	3%	2%	\$7,804	\$7,370	6%	3%
Transfusion Therapies ⁵	\$6	\$9	(33%)	(33%)	\$36	\$46	(22%)	(21%)
Total Baxter - Adjusted ⁴	\$3,594	\$3,498	3%	3%	\$13,893	\$13,056	6%	4%

¹ There were no adjustments included in the 2011 GAAP results or the Q4 2010 GAAP results.

² Principally includes vaccines and sales of plasma to third parties.

³ Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

⁴ Adjusted net sales in the first quarter of 2010 excluded a charge of \$213 million related to the recall of COLLEAGUE infusion pumps. Refer to page 18 for a reconciliation to GAAP measures.

⁵ Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.